Amgen stock climbs 0.28% in pre-market trading

Amgen's stock saw a slight uptick in pre-market trading on October 6, 2026, reaching EUR 360.03 at Lang & Schwarz. This marks a 0.28% increase from the previous close of EUR 359.03 recorded on October 5, 2026. The pre-market bid was EUR 359.15, while the ask stood at EUR 360.90.

The price movement was noted at 8:36 a.m. CEST, with further trading details expected to follow the Xetra open at 9:00 a.m. CEST. The pre-market indication was provided separately from any company-specific news.

In related developments, Amgen had previously announced positive topline Phase 3 results for dazodalibep in treating moderate-to-severe systemic Sjögren's disease. The study, identified as OASIZ 301, was highlighted in Amgen's investor relations news releases on September 22, 2026.